Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp’s psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal.
Source:: Reuters – Business News
Newswire
- [ July 22, 2026 ] Liquidia (NASDAQ: LQDA) Stock Analysis: Can Liquidia Become the Next Great Specialty Pharma? Arena Signals
- [ July 22, 2026 ] Intellia Therapeutics (NASDAQ: NTLA) Stock Analysis: Can CRISPR Deliver Its First Blockbuster? Arena Signals
- [ July 20, 2026 ] Fortress Biotech (NASDAQ: FBIO) Stock Analysis: Building a Biotech Empire—One Deal at a Time Arena Signals
- [ July 17, 2026 ] Fastly (NASDAQ: FSLY) Stock Analysis: Edge Platform Reaches an Inflection Point Arena Signals
- [ July 17, 2026 ] Innoviz Technologies (NASDAQ: INVZ) Stock Analysis: Building the Perception Layer for the Physical AI Revolution Arena Signals
- [ July 17, 2026 ] Neuronetics (NASDAQ: STIM) Stock Analysis: Building an Integrated Mental Health Treatment Platform Arena Signals
- [ July 16, 2026 ] AST SpaceMobile (NASDAQ: ASTS) Stock Analysis: Building World’s First Space-Based Broadband Provider Arena Signals
- [ July 14, 2026 ] GameStop (NYSE: GME) Stock Analysis: Profitable Turnaround — Is Ryan Cohen This Generation’s Warren Buffett? Arena Signals
- [ July 14, 2026 ] Quantum (NASDAQ: QMCO) Stock Analysis: Rebuilding the Data Infrastructure Company for the AI Era Arena Signals
- [ July 14, 2026 ] Expensify (NASDAQ: EXFY) Stock Analysis: Building the AI-Native Financial Superapp for Business Spending Arena Signals
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.